CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Curaleaf Q3 revenue rises 11% on international segment growth 

By Reuters News


Overview

  • U.S. cannabis producer's Q3 revenue rose 11% yr/yr, beating analyst expectations

  • Q3 adjusted EBITDA rose yr/yr to $78 mln

  • Company repurchased shares and expanded retail footprint with new dispensaries


Outlook

  • Company continues to target about $150 mln in operating cash flow for 2026

  • Company says cannabis demand remains resilient despite consumer pressures

  • Curaleaf says it is positioning for sustained growth and greater cash generation


Result Drivers

  • SEGMENT GROWTH - Co said revenue growth was driven by 8% increase in US segment and 28% increase in international segment

  • RETAIL EXPANSION - Co attributed growth in part to opening new dispensaries and expanding retail footprint


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$352.65 mln

$346.83 mln (6 Analysts)

Q3 Loss Per Share

$0.14

Q3 Adjusted EBITDA

$78 mln

Q3 Gross Profit

$170.50 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Curaleaf Holdings, Inc. is C$18.63, about 45.2% above its November 2 closing price of C$12.83


Reuters Recommended Reads

  • Nov 3 - Chegg Q3 revenue falls as legacy business declines

  • Nov 3 - First Watch Q3 revenue slightly beats estimates on new restaurant openings

  • Nov 3 - Yum says Taco Bell rebounding after cyclosporiasis outbreak hit Q3 sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.